Home/Filings/4/0001062993-25-002180
4//SEC Filing

Smith Thomas B 4

Accession 0001062993-25-002180

CIK 0001267565other

Filed

Feb 11, 7:00 PM ET

Accepted

Feb 12, 4:10 PM ET

Size

10.2 KB

Accession

0001062993-25-002180

Insider Transaction Report

Form 4
Period: 2025-02-10
Smith Thomas B
EVP and Chief Medical Officer
Transactions
  • Tax Payment

    Common Stock

    2025-02-10$30.52/sh1,498$45,71992,141 total
  • Tax Payment

    Common Stock

    2025-02-10$30.52/sh4,399$134,25787,742 total
  • Award

    Common Stock

    2025-02-10+33,76288,326 total
  • Award

    Common Stock

    2025-02-10+5,31393,639 total
Footnotes (5)
  • [F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2026, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
  • [F2]Includes 373 and 375 shares acquired on July 19, 2024 and January 17, 2025, respectively, under the Issuer's employee stock purchase plan.
  • [F3]Effective February 10, 2025, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 5,313 performance share units ("PSUs") granted in the Issuer's prior fiscal year.
  • [F4]Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.
  • [F5]Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.

Issuer

COLLEGIUM PHARMACEUTICAL, INC

CIK 0001267565

Entity typeother

Related Parties

1
  • filerCIK 0001748462

Filing Metadata

Form type
4
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 4:10 PM ET
Size
10.2 KB